FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of. Mr. Sandoval’s appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved ...
AptarGroup, Inc. (NYSE:ATR) Q4 2025 Earnings Call Transcript February 6, 2026 Operator: Ladies and gentlemen, thank you for ...
MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced Monday that its recently approved CARDAMYST (etripamil) nasal spray is now available through U.S. retail pharmacies for ...
Credit: Milestone Pharmaceuticals. Each nasal spray device delivers 2 sprays containing a total of etripamil 70mg. The intranasal therapy consists of a novel calcium channel blocker and is designed to ...
MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced Tuesday that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application for etripamil nasal ...
If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the healthcare setting MONTREAL and CHARLOTTE, N.C., Jan.
Hosted on MSN
Milestone’s PSVT nasal spray MAA accepted by EMA
Milestone Pharmaceuticals ( (MIST)) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European Medicines Agency has accepted its Marketing Authorization ...
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) ...
Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results